Barclays says Roche’s (RHHBY) SKY-01 failure is not totally unexpected but likely to be seen as a negative read-through for anti-TIGIT space. However, for Arcus Biosciences (RCUS), low ...

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuster ...

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

Roche announced that the Skyscraper-01 trial studying TIGIT antibody tiragolumab in combination with Roche's approved oncology drug Tecentriq in patients with PD-L1 positive non-small cell lung ...

COM701, a potential first-in-class anti-PVRIG antibody for treating solid tumors, is undergoing phase 1 studies as a single agent and in dual and triple combinations targeting PVRIG, TIGIT and PD-1.

Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in small cell lung cancer (SCLC), in a blow to its ambitions in ...

Since most of the therapeutic TIGIT antibody candidates bind to TIGIT and also mark those cells for destruction by the immune system, including by NK cells, the team hypothesized that activated NK ...

This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus ...